| Drug General Information |
| Drug ID |
D0Z0HH
|
| Former ID |
DNC000701
|
| Drug Name |
Gossypol
|
| Drug Type |
Small molecular drug
|
| Indication |
Prostate cancer [ICD9: 185; ICD10:C61]
|
Phase 2 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C30H30O8
|
| InChI |
InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3
|
| InChIKey |
QBKSWRVVCFFDOT-UHFFFAOYSA-N
|
| CAS Number |
CAS 303-45-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
9869, 106063, 491707, 596303, 597024, 617882, 7351426, 7979433, 8137017, 8139932, 8152224, 10321940, 11112318, 11114252, 11335348, 11341873, 11360587, 11362056, 11363253, 11364415, 11365815, 11366977, 11368377, 11369539, 11372123, 11372790, 11374589, 11375440, 11376539, 11377701, 11405981, 11408781, 11446919, 11461559, 11466705, 11467825, 11485159, 11485423, 11486430, 11487458, 11489288, 11489440, 11490917, 11491331, 11492661, 11493745, 11494173, 11495335, 12013187, 14811578
|
| Target and Pathway |
| Target(s) |
Apoptosis regulator Bcl-2 |
Target Info |
Regulator |
[3]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Focal adhesion
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Prostate cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
Oxidative stress response
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
Ceramide signaling pathway
|
|
Direct p53 effectors
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
ATF-2 transcription factor network
|
|
C-MYB transcription factor network
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Validated targets of C-MYC transcriptional repression
|
|
Reactome
|
Activation of BAD and translocation to mitochondria
|
|
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasome
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
IL-2 Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Focal Adhesion
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
Apoptosis
|
|
Nanoparticle triggered autophagic cell death
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
Prostate Cancer
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Intrinsic Pathway for Apoptosis
|
|
Apoptosis Modulation and Signaling
|
|
TP53 Network
|
|
Influenza A virus infection
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4204). |
|---|
| REF 2 | ClinicalTrials.gov (NCT00848016) Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery. U.S. National Institutes of Health. |
|---|
| REF 3 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. |
|---|
